Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31250394 | 1.00 | HTR2A (0.38) | HTR2AHTR2CCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL25306413 | 0.83 | CHRNB2 (0.37) | HTR2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL31250383 | 0.83 | CHRNB2 (0.37) | HTR2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24952758 | 0.73 | PDGFRB (0.38) | CYP11B2CYP11B1 | |
| SCHEMBL25308429 | 0.69 | CCNT1 (0.38) | HTR2AHTR2CCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL31250389 | 0.68 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25306684 | 0.68 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31654140 | 0.68 | HTR2C (0.46) | HTR2AHTR2CCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL25305763 | 0.68 | HTR2A (0.39) | HTR2AHTR2CCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL31581935 | 0.68 | HTR2C (0.46) | HTR2AHTR2CCHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | HTR2A 3914/4885HTR2C 4265/4885CHRNB2 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.